{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:49:27Z","timestamp":1791395367443,"version":"4.3.3"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004176","name":"Miltenyi Biotec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004176","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06249-z","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T21:43:58Z","timestamp":1751838238000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma"],"prefix":"10.1007","volume":"151","author":[{"given":"Julia K.","family":"Schleifenbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Michel","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybille","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Walzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Mahlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"6249_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-Cell lymphomas (Transcend Nhl 001): a multicentre seamless design study. Lancet 396:839\u2013852","journal-title":"Lancet"},{"issue":"19","key":"6249_CR2","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1182\/bloodadvances.2023010127","volume":"7","author":"OS Akhtar","year":"2023","unstructured":"Akhtar OS, Cao B, Wang X, Torka P, Al-Jumayli M, Locke FL, Freeman CL (2023) CAR T-Cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response. Blood Adv 7(19):5937\u20135940","journal-title":"Blood Adv"},{"issue":"3","key":"6249_CR3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","volume":"4","author":"R Awasthi","year":"2020","unstructured":"Awasthi R, Pacaud L, Waldron E, Tam CS, J\u00e4ger U, Borchmann P, Jaglowski S, Foley SR, Van Besien K, Wagner-Johnston ND, Kersten MJ, Schuster SJ, Salles G, Maziarz RT, Anak \u00d6, Del Corral C, Chu J, Gershgorin I, Pruteanu-Malinici I, Chakraborty A, Mueller KT, Waller EK (2020) Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL. Blood Adv 4(3):560\u2013572","journal-title":"Blood Adv"},{"issue":"11","key":"6249_CR4","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1182\/bloodadvances.2020003959","volume":"5","author":"FA Ayuk","year":"2021","unstructured":"Ayuk FA, Berger C, Badbaran A, Zabelina T, Sonntag T, Riecken K, Geffken M, Wichmann D, Frenzel C, Thayssen G, Zeschke S, Kr\u00f6ger N, Fehse B (2021) Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-Cell lymphoma in a real-world setting. Blood Adv 5(11):2523\u20132527","journal-title":"Blood Adv"},{"key":"6249_CR5","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, Beauvais D, Roulin L, Gros FX, Rubio MT, Bories P, Bay JO, Llorente CC, Choquet S, Casasnovas RO, Mohty M, Guidez S, Joris M, Loschi M, Carras S, Abraham J, Chauchet A, Drieu La Rochelle L, Deau-Fischer B, Hermine O, Gastinne T, Tudesq JJ, Gat E, Broussais F, Thieblemont C, Houot R, Morschhauser F (2022) A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 28:2145\u20132154","journal-title":"Nat Med"},{"key":"6249_CR6","doi-asserted-by":"publisher","first-page":"855730","DOI":"10.3389\/fimmu.2022.855730","volume":"13","author":"M Bastos-Oreiro","year":"2022","unstructured":"Bastos-Oreiro M, Gutierrez A, Reguera JL, Iacoboni G, L\u00f3pez-Corral L, Terol MJ, Ort\u00edz-Maldonado V, Sanz J, Guerra-Dominguez L, Bailen R, Mussetti A, Abrisqueta P, Hernani R, Luzardo H, Sancho JM, Delgado-Serrano J, Salar A, Grande C, Bento L, Gonz\u00e1lez De Villambros\u00eda S, Garc\u00eda-Belmonte D, Sureda A, P\u00e9rez-Mart\u00ednez A, Barba P, Kwon M, Mart\u00edn Garc\u00eda-Sancho A (2022) Best treatment option for patients with refractory aggressive B-cell lymphoma in the CAR-T Cell era: real-world evidence from GALTEMO\/GETH Spanish groups. Front Immunol 13:855730","journal-title":"Front Immunol"},{"key":"6249_CR7","first-page":"349","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, Von Tresckow B, Ayuk F, Wagner-Drouet EM, Wulf GG, Marks R, Penack O, Schnetzke U, Koenecke C, Von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp M, Fante MA, Schroers R, Bayir L, Borchmann P, Buecklein V, Hasenkamp J, Hanoun C, Thomas S, Beelen DW, Lengerke C, Kroeger N, Dreger P (2022) GLA\/DRST real-world outcome analysis of CAR T-Cell therapies for large B-Cell lymphoma in Germany. Blood 140:349\u2013358","journal-title":"Blood"},{"key":"6249_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/ejh.13968","volume":"111","author":"O Beyar Katz","year":"2023","unstructured":"Beyar Katz O, Perry C, Grisariu-Greenzaid S, Yehudai-Ofir D, Luttwak E, Avni B, Zuckerman T, Sdayoor I, Stepensky P, Ringelstein-Harlev S, Bar-On Y, Libster D, Sharvit L, Amit O, Greenbaum U, Gold R, Herishanu Y, Benyamini N, Avivi I, Ram R (2023) Response rates of extra-nodal diffuse large B Cell lymphoma To Anti-CD19-CAR T cells: A real word retrospective multicenter study. Eur J Haematol 111:63\u201371","journal-title":"Eur J Haematol"},{"key":"6249_CR9","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1182\/bloodadvances.2022008937","volume":"7","author":"ST Bhaskar","year":"2023","unstructured":"Bhaskar ST, Patel VG, Porter DL, Schuster SJ, Nastoupil LJ, Perales MA, Tomas AA, Bishop MR, Mcguirk JP, Maziarz RT, Chen AI, Bachanova V, Maakaron JE, Riedell PA, Oluwole OO (2023) chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv 7:4765\u20134772","journal-title":"Blood Adv"},{"key":"6249_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, M\u00fcller AMS, Maziarz RT, Mcguirk JP, Bachy E, Gouill SL, Dreyling M, Harigae H, Bond D, Andreadis C, Mcsweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, J\u00e4ger U, Borchmann P, Westin JR (2022) Second-line tisagenlecleucel or standard care in aggressive B-cell Lymphoma. N Engl J Med 386:629\u2013639","journal-title":"N Engl J Med"},{"issue":"22","key":"6249_CR11","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.1182\/bloodadvances.2023010364","volume":"7","author":"V Blumenberg","year":"2023","unstructured":"Blumenberg V, Galina B, Baumann S, Jitschin R, Iacoboni G, Hoster E, Gallur L, Iraola-Truchuelo J, Winkelmann M, Hellwig K, Schmidt C, Fr\u00f6lich L, Tast B, Hildebrand F, Rejeski K, Dekorsy FJ, Schmidkonz C, B\u00e4uerle T, Kunz WG, Mougiakakos D, M\u00fcller F, Von Bergwelt-Baildon M, Barba P, B\u00fccklein VL, Mackensen A, V\u00f6lkl S, Subklewe M (2023) Early quantification of anti-CD19 CAR T-cells by flow cytometry predicts response in R\/R DLBCL. Blood Adv 7(22):6844\u20136849","journal-title":"Blood Adv"},{"key":"6249_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40487-022-00211-6","volume":"11","author":"P Borchmann","year":"2023","unstructured":"Borchmann P, Heger JM, Mahlich J, Papadimitrious MS, Riou S, Werner B (2023) Healthcare resource utilization and associated costs of German patients with diffuse large B-Cell lymphoma: a retrospective health claims data analysis. Oncol Ther 11:65\u201381","journal-title":"Oncol Ther"},{"key":"6249_CR13","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1182\/bloodadvances.2021006563","volume":"7","author":"E Bourbon","year":"2023","unstructured":"Bourbon E, Sesques P, Gossez M, Tordo J, Ferrant E, Safar V, Wallet F, Aussedat G, Maarek A, Bouafia F, Karlin L, Ghergus D, Golfier C, Lequeu H, Lazareth A, Schwiertz V, Viel S, Idlhaj M, Ghesqui\u00e8res H, Monneret G, Bachy E, Venet F (2023) HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-Cell therapy for large B-Cell lymphoma. Blood Adv 7:744\u2013755","journal-title":"Blood Adv"},{"key":"6249_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","volume":"6","author":"MM Boyiadzis","year":"2018","unstructured":"Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR (2018) Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer 6:137","journal-title":"J Immunother Cancer"},{"key":"6249_CR15","doi-asserted-by":"publisher","first-page":"E907","DOI":"10.1097\/HS9.0000000000000907","volume":"7","author":"V B\u00fccklein","year":"2023","unstructured":"B\u00fccklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, Kharboutli S, Blumenberg V, Ackermann J, Fr\u00f6lich L, Johnson G, Patel K, Arciola B, Mhaskar R, Wood A, Schmidt C, Albanyan O, G\u00f6del P, Hoster E, Bullinger L, Mackensen A, Locke F, Von Bergwelt M, Barba P, Subklewe M, Jain MD (2023) Inferior outcomes of EU versus US patients treated with CD19 CAR-T for relapsed\/refractory large B-Cell lymphoma: association with differences in tumor burden, systemic inflammation, bridging therapy utilization and CAR-T product use. Hemasphere 7:E907","journal-title":"Hemasphere"},{"key":"6249_CR16","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1001\/jamaoncol.2022.3738","volume":"8","author":"OH Butt","year":"2022","unstructured":"Butt OH, Zhou AY, Caimi PF, Luckett PH, Wisch JK, Derenoncourt PR, Lee K, Wu GF, De Lima MJG, Campian JL, Frank MJ, Dipersio JF, Ghobadi A, Ances BM (2022) Assessment of pretreatment and posttreatment evolution of neurofilament light chain levels in patients who develop immune effector cell-associated neurotoxicity syndrome. JAMA Oncol 8:1652\u20131657","journal-title":"JAMA Oncol"},{"key":"6249_CR17","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.20.01467","volume":"38","author":"KM Cappell","year":"2020","unstructured":"Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, Mcintyre L, Rosenberg SA, Kochenderfer JN (2020) Long-term follow-up of anti-CD19 chimeric antigen receptor T-Cell therapy. J Clin Oncol 38:3805\u20133815","journal-title":"J Clin Oncol"},{"key":"6249_CR18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood.2022015601","volume":"140","author":"HJJ Cherng","year":"2022","unstructured":"Cherng HJJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J (2022) Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-Cell therapy for large B-Cell lymphoma. Blood 140:504\u2013515","journal-title":"Blood"},{"key":"6249_CR19","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1182\/blood.2023020197","volume":"142","author":"D Chihara","year":"2023","unstructured":"Chihara D, Liao L, Tkacz J, Franco A, Lewing B, Kilgore KM, Nastoupil LJ, Chen L (2023) Real-world experience of CAR T-Cell therapy in older patients with relapsed\/refractory diffuse large B-Cell lymphoma. Blood 142:1047\u20131055","journal-title":"Blood"},{"key":"6249_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jcyt.2022.10.010","volume":"25","author":"X Dang","year":"2023","unstructured":"Dang X, Ye S, Zhou L, Lu Y, Li P, Liang A, Qian W (2023) Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-Cell lymphoma receiving chimeric antigen receptor T-Cell therapy. Cytotherapy 25:573\u2013577","journal-title":"Cytotherapy"},{"key":"6249_CR21","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1182\/bloodadvances.2022009426","volume":"7","author":"EA Dean","year":"2023","unstructured":"Dean EA, Kimmel GJ, Frank MJ, Bukhari A, Hossain NM, Jain MD, Dahiya S, Miklos DB, Altrock PM, Locke FL (2023) Circulating tumor DNA adds specificity to pet after axicabtagene ciloleucel in large B-Cell lymphoma. Blood Adv 7:4608\u20134618","journal-title":"Blood Adv"},{"key":"6249_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12149-020-01544-w","volume":"35","author":"T Derlin","year":"2021","unstructured":"Derlin T, Schultze-Florey C, Werner RA, M\u00f6hn N, Skripuletz T, David S, Beutel G, Eder M, Ross TL, Bengel FM, Ganser A, Koenecke C (2021) 18F-FDG P\/CtT of off-target lymphoid organs In CD19-targeting chimeric antigen receptor T-Cell therapy for relapsed or refractory diffuse large B-Cell lymphoma. Ann Nucl Med 35:132\u2013138","journal-title":"Ann Nucl Med"},{"key":"6249_CR23","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1080\/10428194.2020.1849676","volume":"62","author":"A Di Rocco","year":"2021","unstructured":"Di Rocco A, Cuneo A, Di Rocco A, Merli F, De Luca G, Petrucci L, Ansuinelli M, Penna D, Rotondo F, Rigolin GM, Giaimo M, Re F, Farcomeni A, Martelli M, Fo\u00e0 R (2021) Relapsed\/refractory diffuse large B-Cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for CAR-T Cell therapy. Leukemia Lymphoma 62:828\u2013836","journal-title":"Leukemia Lymphoma"},{"key":"6249_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1089\/jir.2021.0057","volume":"41","author":"R Dong","year":"2021","unstructured":"Dong R, Jiang S, Chen Y, Ma Y, Sun L, Xing C, Zhang S, Yu K (2021) Prognostic significance of cytokine release syndrome in B cell hematological malignancies patients after chimeric antigen receptor T Cell therapy. J Interferon Cytokine Res 41:469\u2013476","journal-title":"J Interferon Cytokine Res"},{"key":"6249_CR25","doi-asserted-by":"publisher","first-page":"6157","DOI":"10.1182\/bloodadvances.2020003036","volume":"4","author":"P Dreger","year":"2020","unstructured":"Dreger P, Dietrich S, Schubert ML, Selberg L, Bondong A, Wegner M, Stadtherr P, Kimmich C, Kosely F, Schmitt A, Pavel P, Liebers N, Luft T, Hegenbart U, Radujkovic A, Ho AD, M\u00fcller-Tidow C, Schmitt M (2020) CAR T cells or allogeneic transplantation as standard of care for advanced large B-Cell lymphoma: an intent-to-treat comparison. Blood Adv 4:6157\u20136168","journal-title":"Blood Adv"},{"key":"6249_CR26","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","volume":"26","author":"R Faramand","year":"2020","unstructured":"Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML (2020) Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-Cell lymphoma treated with axicabtagene ciloleucel. Clin Cancer Res 26:4823\u20134831","journal-title":"Clin Cancer Res"},{"key":"6249_CR27","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.ijrobp.2021.06.038","volume":"111","author":"NB Figura","year":"2021","unstructured":"Figura NB, Robinson TJ, Sim AJ, Wang X, Cao B, Chavez JC, Shah BD, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu HD, Kim S, Locke FL, Jain MD (2021) Patterns and predictors of failure in recurrent or refractory large B-Cell lymphomas after chimeric antigen receptor T-Cell therapy. Int J Radiat Oncol Biol Phys 111:1145\u20131154","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6249_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.hemonc.2021.09.001","volume":"16","author":"JV Forero-Forero","year":"2023","unstructured":"Forero-Forero JV, Lengerke-Diaz PA, Moreno-Cortes E, Melody M, Rahman ZA, Rosenthal AC, Kharfan-Dabaja MA, Castro JE (2023) Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-Cell lymphoma. Hematol Oncol Stem Cell Ther 16:133\u2013143","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"6249_CR29","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.21.00377","volume":"39","author":"MJ Frank","year":"2021","unstructured":"Frank MJ, Hossain NM, Bukhari A, Dean E, Spiegel JY, Claire GK, Kirsch I, Jacob AP, Mullins CD, Lee LW, Kong KA, Craig J, Mackall CL, Rapoport AP, Jain MD, Dahiya S, Locke FL, Miklos DB (2021) Monitoring of circulating tumor dna improves early relapse detection after axicabtagene ciloleucel infusion in large B-Cell lymphoma: results of a prospective multi-institutional trial. J Clin Oncol 39:3034\u20133043","journal-title":"J Clin Oncol"},{"key":"6249_CR30","first-page":"233","volume":"27","author":"M Garcia-Recio","year":"2021","unstructured":"Garcia-Recio M, Wudhikarn K, Pennisi M, Alonso-Trillo R, Flynn J, Shouval R, Afuye AO, Silverberg ML, Batlevi CW, Dahi P, Devlin S, Giralt SA, Halton E, Ruiz J, Maloy M, Mead E, Palomba ML, Santomasso B, Sauter CS, Scordo M, Shah GL, Perales MA (2021) The international prognostic index is associated with outcomes in diffuse large B cell lymphoma after CAR T Cell therapy. Trans Cell Therapy 27:233\u2013240","journal-title":"Trans Cell Therapy"},{"issue":"17","key":"6249_CR31","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.3390\/cancers15174253","volume":"15","author":"E Gavriilaki","year":"2023","unstructured":"Gavriilaki E, Mallouri D, Bousiou Z, Demosthenous C, Vardi A, Dolgyras P, Batsis I, Stroggyli E, Karvouni P, Masmanidou M, Gavriilaki M, Bouinta A, Bitsianis S, Kapravelos N, Bitzani M, Vasileiadou G, Yannaki E, Sotiropoulos D, Papagiannopoulos S, Kazis D, Kimiskidis V, Anagnostopoulos A, Sakellari I (2023) Molecular and clinical characteristics of different toxicity rates in Anti-CD19 chimeric antigen receptor T Cells: real-world experience. Cancers 15(17):4253","journal-title":"Cancers"},{"key":"6249_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.clml.2021.07.002","volume":"21","author":"S Ghafouri","year":"2021","unstructured":"Ghafouri S, Fenerty K, Schiller G, De Vos S, Eradat H, Timmerman J, Larson S, Mead M (2021) Real-world experience of axicabtagene ciloleucel and tisagenlecleucel for relapsed or refractory aggressive B-Cell lymphomas: a single-institution experience. Clin Lymphoma Myeloma Leukemia 21:861\u2013872","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"6249_CR33","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s10147-023-02334-w","volume":"28","author":"H Goto","year":"2023","unstructured":"Goto H, Kitawaki T, Fujii N, Kato K, Onishi Y, Fukuhara N, Yamauchi T, Toratani K, Kobayashi H, Yoshida S, Shimo M, Onodera K, Senjo H, Onozawa M, Hirata K, Yokota I, Teshima T (2023) Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-Cell lymphoma: the first real-world evidence in Japan. Int J Clin Oncol 28:816\u2013826","journal-title":"Int J Clin Oncol"},{"key":"6249_CR34","doi-asserted-by":"publisher","first-page":"565236","DOI":"10.3389\/fimmu.2020.565236","volume":"11","author":"M Gotti","year":"2020","unstructured":"Gotti M, Defrancesco I, D\u2019angelo M, Basso S, Crotto L, Marinelli A, Maccalli C, Iaconianni V (2020) Cancer immunotherapy using chimeric antigen receptor expressing T-Cells: present and future needs of clinical cancer centers. Front Immunol 11:565236","journal-title":"Front Immunol"},{"key":"6249_CR35","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","volume":"5","author":"U Greenbaum","year":"2021","unstructured":"Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S (2021) CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5:2799\u20132806","journal-title":"Blood Adv"},{"issue":"9","key":"6249_CR36","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.3390\/cancers15092411","volume":"15","author":"A Guarini","year":"2023","unstructured":"Guarini A, Radice G, Peragine N, Buracchi C, De Propris MS, Di Rocco A, Di Rocco A, Chiaretti S, Moretti A, Napolitano S, Martelli M, Balduzzi A, Gaipa G, Biondi A, Fo\u00e0 R (2023) Long-term host immune modulation following tisagenlecleucel administration in patients with diffuse large B-Cell lymphoma and B-Lineage acute lymphoblastic leukemia. Cancers 15(9):2411","journal-title":"Cancers"},{"key":"6249_CR37","first-page":"S242","volume":"422346","author":"B Guffroy","year":"2024","unstructured":"Guffroy B, Bachy E, Di Blasi R, Hanane Guedon H, Le Bras F, Yakoub-Agha I, Guidez S, Ricard L, Gastinne T, Castilla-Llorente C, De Croocq J, Brisou G, Choquet S, Casasnovas O, Loschi M, Bay JO, Jardin F, Gat E, Le Gouill S, Houot R, Bories P (2024) Real-world assessment of anti-CD19 Car-T Cells in patients aged 75 years and older with relapsed or refractory large B-Cell lymphoma: a LYSA study from the DESCAR-T registry. EHA Library 422346:S242","journal-title":"EHA Library"},{"key":"6249_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/cncr.34532","volume":"129","author":"A Guidetti","year":"2023","unstructured":"Guidetti A, Dodero A, Lorenzoni A, Pizzamiglio S, Argiroffi G, Chiappella A, Bagnoli F, Marasco V, Carniti C, Monfrini C, Seregni E, Pennisi M, Verderio P, Alessi A, Corradini P (2023) Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy. Cancer 129:255\u2013263","journal-title":"Cancer"},{"key":"6249_CR39","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1053\/j.seminoncol.2010.04.001","volume":"37","author":"S Halabi","year":"2010","unstructured":"Halabi S, Owzar K (2010) The importance of identifying and validating prognostic factors in oncology. Semin Oncol 37:E9-18","journal-title":"Semin Oncol"},{"key":"6249_CR40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","volume":"23","author":"NG Holtzman","year":"2021","unstructured":"Holtzman NG, Xie H, Bentzen S, Kesari V, Bukhari A, El Chaer F, Lutfi F, Siglin J, Hutnick E, Gahres N, Ruehle K, Ahmad H, Shanholtz C, Kocoglu MH, Badros AZ, Yared JA, Hardy NM, Rapoport AP, Dahiya S (2021) Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-Cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro Oncol 23:112\u2013121","journal-title":"Neuro Oncol"},{"key":"6249_CR41","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1002\/cam4.3881","volume":"10","author":"G Iacoboni","year":"2021","unstructured":"Iacoboni G, Villacampa G, Martinez-Cibrian N, Bail\u00e9n R, Lopez Corral L, Sanchez JM, Guerreiro M, Caballero AC, Mussetti A, Sancho JM, Hernani R, Abrisqueta P, Solano C, Sureda A, Briones J, Martin Garcia-Sancho A, Kwon M, Reguera-Ortega JL, Barba P (2021) Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-Cell lymphoma. Cancer Med 10:3214\u20133223","journal-title":"Cancer Med"},{"key":"6249_CR42","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1111\/jcmm.17550","volume":"26","author":"L Iovino","year":"2022","unstructured":"Iovino L, Wu QV, Voutsinas J, Panaite L, Mullane E, Lynch RC, Ujjani C, Smith SD, Gopal AK, Till BG, Milano F, Chow V, Gauthier J, Turtle CJ, Maloney DG, Shadman M (2022) Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: a real-world study. J Cell Mol Med 26:5976\u20135983","journal-title":"J Cell Mol Med"},{"key":"6249_CR43","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.clml.2022.05.004","volume":"22","author":"MT Jacobs","year":"2022","unstructured":"Jacobs MT, Jain MD, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan PM, Oluwole OO, Mcguirk J, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Ghobadi A, Locke FL (2022) Severity of cytokine release syndrome influences outcome after axicabtagene ciloleucel for large B cell lymphoma: results from the US lymphoma CAR-T consortium. Clin Lymphoma Myeloma Leukemia 22:753\u2013759","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"6249_CR44","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1200\/JCO.19.02103","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH (2020) Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol 38:3095\u20133106","journal-title":"J Clin Oncol"},{"key":"6249_CR45","doi-asserted-by":"publisher","first-page":"581.E1","DOI":"10.1016\/j.jtct.2022.05.026","volume":"28","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, Dong H, Nikiforow S, Hooper M, Kawashima J, Xu H, Pasquini MC (2022) Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transplant Cell Ther 28:581.E1-581.E8","journal-title":"Transplant Cell Ther"},{"key":"6249_CR46","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1182\/bloodadvances.2023011489","volume":"8","author":"MD Jain","year":"2024","unstructured":"Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, Mcguirk J, Deol A, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos D, Neelapu SS, Locke FL, Ghobadi A (2024) Bridging therapy with axicabtagene ciloleucel for large B-Cell lymphoma: results from the US lymphoma CAR-T consortium. Blood Adv 8:1042\u20131050","journal-title":"Blood Adv"},{"key":"6249_CR47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","volume":"63","author":"G Kanas","year":"2022","unstructured":"Kanas G, Ge W, Quek RGW, Keeven K, Nersesyan K, Jon EA (2022) Epidemiology of diffuse large B-Cell lymphoma (DLBCL) and follicular lymphoma (Fl) in the United States and Western Europe: population-level projections for 2020\u20132025. Leuk Lymphoma 63:54\u201363","journal-title":"Leuk Lymphoma"},{"key":"6249_CR48","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Nicolas Gonzalez Castro L, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J (2019) Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T Cells. Blood 133:2212\u20132221","journal-title":"Blood"},{"key":"6249_CR49","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","volume":"11","author":"M Khalil","year":"2020","unstructured":"Khalil M, Pirpamer L, Hofer E, Voortman MM, Barro C, Leppert D, Benkert P, Ropele S, Enzinger C, Fazekas F, Schmidt R, Kuhle J (2020) Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun 11:812","journal-title":"Nat Commun"},{"key":"6249_CR50","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RP, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, Mcintyre L, Toomey MA, Rosenberg SA (2017) Lymphoma remissions caused by Anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol 35:1803\u20131813","journal-title":"J Clin Oncol"},{"key":"6249_CR51","doi-asserted-by":"publisher","first-page":"877477","DOI":"10.3389\/fimmu.2022.877477","volume":"13","author":"F Korell","year":"2022","unstructured":"Korell F, Penack O, Mattie M, Schreck N, Benner A, Krzykalla J, Wang Z, Schmitt M, Bullinger L, M\u00fcller-Tidow C, Dreger P, Luft T (2022) EASIX and severe endothelial complications after CD19-directed car-t cell therapy\u2014a cohort study. Front Immunol 13:877477","journal-title":"Front Immunol"},{"key":"6249_CR52","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3324\/haematol.2022.280805","volume":"108","author":"M Kwon","year":"2023","unstructured":"Kwon M, Iacoboni G, Reguera JL, L\u00f3pez Corral L, Morales RH, Ortiz-Maldonado V, Guerreiro M, Caballero AC, Dom\u00ednguez MLG, Pina JMS, Mussetti A, Sancho JM, Bastos-Oreiro M, Catala E, Delgado J, Henriquez HL, Sanz J, Calbacho M, Bail\u00e9n R, Carpio C, Ribera JM, Sureda A, Briones J, Hernandez-Boluda JC, Cebri\u00e1n NM, Martin JLD, Mart\u00edn A, Barba P (2023) Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-Cell lymphoma. Haematologica 108:110\u2013121","journal-title":"Haematologica"},{"issue":"6","key":"6249_CR53","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.3390\/cancers15061747","volume":"15","author":"C Ladbury","year":"2023","unstructured":"Ladbury C, Dandapani S, Hao C, Fabros M, Amini A, Sampath S, Glaser S, Sokolov K, Yeh J, Baird JH, Kambhampati S, Herrera A, Mei M, Nikolaenko L, Shouse G, Budde LE (2023) Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed\/refractory large B Cell lymphoma. Cancers 15(6):1747","journal-title":"Cancers"},{"issue":"2","key":"6249_CR54","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/biom13020382","volume":"13","author":"T Lakomy","year":"2023","unstructured":"Lakomy T, Akhoundova D, Nilius H, Kronig MN, Novak U, Daskalakis M, Bacher U, Pabst T (2023) Early use of corticosteroids following CAR T-Cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome. Biomolecules 13(2):382","journal-title":"Biomolecules"},{"issue":"17","key":"6249_CR55","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.3390\/cancers13174279","volume":"13","author":"S Lamure","year":"2021","unstructured":"Lamure S, Van Laethem F, De Verbizier D, Lozano C, Gehlkopf E, Tudesq JJ, Serrand C, Benzaoui M, Kanouni T, Quintard A, De Vos J, Tchernonog E, Platon L, Ayrignac X, Ceballos P, Sirvent A, Fran\u00e7ois M, Guedon H, Quittet P, Mongellaz C, Conte A, Herbaux C, Bret C, Taylor N, Dardalhon V, Cartron G (2021) Clinical and product features associated with outcome of DLBCL patients to CD19-targeted CAR T-Cell therapy. Cancers 13(17):4279","journal-title":"Cancers"},{"key":"6249_CR56","first-page":"495","volume":"29","author":"DJ Landsburg","year":"2023","unstructured":"Landsburg DJ, Nasta SD, Svoboda J, Gerson JN, Schuster SJ, Barta SK, Chong EA, Difilippo H, Weber E, Cunningham K, Catania C, Garfall AL, Stadtmauer EA, Frey NV, Porter DL (2023) Survival outcomes for patients with relapsed\/ refractory aggressive B Cell lymphomas following receipt of high-dose chemotherapy\/autologous stem transplantation and\/or chimeric antigen receptor-modified T Cells. Trans Cell Therapy 29:495\u2013503","journal-title":"Trans Cell Therapy"},{"key":"6249_CR57","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11912-016-0539-4","volume":"18","author":"H Lennon","year":"2016","unstructured":"Lennon H, Sperrin M, Badrick E, Renehan AG (2016) The obesity paradox in cancer: a review. Curr Oncol Rep 18:56","journal-title":"Curr Oncol Rep"},{"key":"6249_CR58","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","volume":"27","author":"H Liu","year":"2021","unstructured":"Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, Guo X, Chen Z, Lu Y, Young KH, Lu Z, Qian W (2021) CD19-specific CAR T cells that express APD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-Cell lymphoma. Clin Cancer Res 27:473\u2013484","journal-title":"Clin Cancer Res"},{"key":"6249_CR59","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, Oluwole OO, Reagan PM, Lekakis LJ, Lin Y, Sherman M, Better M, Go WY, Wiezorek JS, Xue A, Bot A (2020) Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-Cell lymphoma. Blood Adv 4:4898\u20134911","journal-title":"Blood Adv"},{"key":"6249_CR60","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, Mcguirk J, Pagel JM, Mu\u00f1oz J, Farooq U, Van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR (2022) Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma. N Engl J Med 386:640\u2013654","journal-title":"N Engl J Med"},{"key":"6249_CR61","doi-asserted-by":"publisher","first-page":"E414","DOI":"10.1016\/S2352-3026(17)30108-4","volume":"4","author":"T Luft","year":"2017","unstructured":"Luft T, Benner A, Jodele S, Dandoy CE, Storb R, Gooley T, Sandmaier BM, Becker N, Radujkovic A, Dreger P, Penack O (2017) EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol 4:E414\u2013E423","journal-title":"Lancet Haematol"},{"key":"6249_CR62","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/ejh.13609","volume":"107","author":"M Melody","year":"2021","unstructured":"Melody M, Gandhi S, Rahman ZA, Lengerke-Diaz P, Gannon N, Rosenthal A, Truong T, Novo M, Brandes E, Lange G, Estby B, Johnston P, Ansell S, Bennani NN, Paludo J, Bisneto JV, Ayala E, Tun HW, Murthy HS, Roy V, Foran J, Castro J, Lin Y, Kharfan-Dabaja MA (2021) Impact of hypoalbuminemia on the prognosis of relapsed\/refractory B-Cell lymphoma treated with axicabtagene ciloleucel. Eur J Haematol 107:48\u201353","journal-title":"Eur J Haematol"},{"key":"6249_CR63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41408-019-0247-z","volume":"9","author":"A Merz","year":"2019","unstructured":"Merz A, Germing U, Kobbe G, Kaivers J, Jauch A, Radujkovic A, Hummel M, Benner A, Merz M, Dreger P, Luft T (2019) EASIX for prediction of survival in lower-risk myelodysplastic syndromes. Blood Cancer J 9:85","journal-title":"Blood Cancer J"},{"key":"6249_CR64","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/hematology.2023000436","volume":"2023","author":"A Mussetti","year":"2023","unstructured":"Mussetti A, Fabbri N, Sureda A (2023) CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers. Hematology Am Soc Hematol Educ Program 2023:357\u2013363","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"6249_CR65","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, Mcguirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL (2020) Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol 38:3119\u20133128","journal-title":"J Clin Oncol"},{"key":"6249_CR66","first-page":"751.E1","volume":"28","author":"K Nath","year":"2022","unstructured":"Nath K, Tomas AA, Flynn J, Fein JA, Alperovich A, Anagnostou T, Batlevi CL, Dahi PB, Fingrut WB, Giralt SA, Lin RJ, Palomba ML, Peled JU, Salles G, Sauter CS, Scordo M, Fraint E, Feuer E, Shah N, Slingerland JB, Devlin S, Shah GL, Gupta G, Perales MA, Shouval R (2022) Vitamin D insufficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in large B-Cell lymphoma. Trans Cell Therapy 28:751.E1-751.E7","journal-title":"Trans Cell Therapy"},{"key":"6249_CR67","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, Mcsweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med 377:2531\u20132544","journal-title":"N Engl J Med"},{"key":"6249_CR68","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood.2019004162","volume":"135","author":"SS Neelapu","year":"2020","unstructured":"Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, Bartlett NL, Braunschweig I, Jiang Y, Kim JJ, Zheng L, Rossi JM, Locke FL (2020) Outcomes of older patients In ZUMA -1, a pivotal study of axicabtagene ciloleucel in refractory large B-Cell lymphoma. Blood 135:2106\u20132109","journal-title":"Blood"},{"key":"6249_CR69","doi-asserted-by":"publisher","first-page":"N71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Mckenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, Mcdonald S, Mcguinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA (2020) statement: an updated guideline for reporting systematic reviews. BMJ 372:N71","journal-title":"BMJ"},{"key":"6249_CR70","doi-asserted-by":"crossref","unstructured":"Penack O, Peczynski C, Koenecke C, Polge E, Kuhnl A, Fegueux N, Daskalakis M, Kr\u00f6ger N, Dreger P, Besley C, Schanz U, Bloor A, Ganser A, Forcade E, L\u00f3pez Corral L, Passweg JR, Novak U, Moiseev I, Schoemans H, Basak GW, Chabannon C, Sureda A, Averbuch D, Glass B, De La Camara R, Peric Z (2023) Severe cytopenia after CD19 CAR T-Cell therapy: a retrospective study from the EBMT transplant complications working party. J Immun Cancer 11(4):e006406","DOI":"10.1136\/jitc-2022-006406"},{"key":"6249_CR71","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","volume":"107","author":"R Ram","year":"2022","unstructured":"Ram R, Grisariu S, Shargian-Alon L, Amit O, Bar-On Y, Stepensky P, Yeshurun M, Avni B, Hagin D, Perry C, Gurion R, Sarid N, Herishanu Y, Gold R, Glait-Santar C, Kay S, Avivi I (2022) Toxicity and efficacy of chimeric antigen receptor T-Cell therapy in patients with diffuse large B-Cell lymphoma above the age of 70 years compared to younger patients\u2013 a matched control multicenter cohort study. Haematologica 107:1111\u20131118","journal-title":"Haematologica"},{"key":"6249_CR72","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1158\/2326-6066.CIR-22-0487","volume":"11","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Cordas Dos Santos DM, Parker NH, B\u00fccklein VL, Winkelmann M, Jhaveri KS, Liu L, Trinkner P, G\u00fcnther S, Karschnia P, Blumenberg V, Schmidt C, Kunz WG, Von Bergwelt-Baildon M, Jain MD, Theurich S, Subklewe M (2023) Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-Cell therapy. Cancer Immunol Res 11:707\u2013719","journal-title":"Cancer Immunol Res"},{"key":"6249_CR73","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/blood-2023-184862","volume":"142","author":"PA Riedell","year":"2023","unstructured":"Riedell PA, Grady C, Nastoupil LJ, Luna A, Ahmed N, Maziarz RT, Hu M, Brower J, Hwang W-T, Schuster SJ, Chen A, Oluwole OO, Bachanova V, Mcguirk JP, Perales M-A, Bishop MR, Porter DL (2023) Lisocabtagene maraleucel in relapsed\/refractory large B-Cell lymphoma: real world analysis from the cell therapy consortium. Blood 142:617","journal-title":"Blood"},{"issue":"8","key":"6249_CR74","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/cancers17081335","volume":"17","author":"S Riou","year":"2025","unstructured":"Riou S, Rungaldier S, Mahlich J (2025) Identification of adjustment variables in indirect comparisons: a rapid review of CAR-T therapies for diffuse large B-Cell lymphoma. Cancers 17(8):1335","journal-title":"Cancers"},{"key":"6249_CR75","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood.2018883421","volume":"134","author":"CS Sauter","year":"2019","unstructured":"Sauter CS, Senechal B, Rivi\u00e8re I, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Singh AN, Szenes VZ, Yoo S, Dogan A, Wang Y, Moskowitz CH, Giralt S, Matasar MJ, Perales MA, Curran KJ, Park J, Sadelain M, Brentjens RJ (2019) CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-Cell non-hodgkin lymphoma. Blood 134:626\u2013635","journal-title":"Blood"},{"key":"6249_CR76","doi-asserted-by":"publisher","first-page":"8901","DOI":"10.2147\/CMAR.S321202","volume":"13","author":"A Schaefer","year":"2021","unstructured":"Schaefer A, Huang Y, Kittai A, Maakaron JE, Saygin C, Brammer J, Penza S, Saad A, Jaglowski SM, William BM (2021) Cytopenias after CD19 chimeric antigen receptor T-Cells (CAR-T) therapy for diffuse large B-Cell lymphomas or transformed follicular lymphoma: a single institution experience. Cancer Manag Res 13:8901\u20138906","journal-title":"Cancer Manag Res"},{"key":"6249_CR77","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","volume":"6","author":"F Schoeberl","year":"2022","unstructured":"Schoeberl F, Tiedt S, Schmitt A, Blumenberg V, Karschnia P, Burbano VG, Bucklein VL, Rejeski K, Schmidt C, Busch G, Von Bergwelt-Baildon M, Tonn JC, Schmitt M, Subklewe M, Von Baumgarten L (2022) Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-Cell treatment. Blood Adv 6:3022\u20133026","journal-title":"Blood Adv"},{"key":"6249_CR78","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, Chang EC, Neelapu SS, Miklos DB, Jacobson CA, Lekakis LJ, Lin Y, Ghobadi A, Kim JJ, Chou J, Plaks V, Wang Z, Xue A, Mattie M, Rossi JM, Bot A, Galon J (2022) Tumor immune contexture is a determinant of Anti-Cd19 Car T cell efficacy in large B Cell lymphoma. Nat Med 28:1872\u20131882","journal-title":"Nat Med"},{"issue":"7","key":"6249_CR79","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.3390\/jcm12072553","volume":"12","author":"D Schult","year":"2023","unstructured":"Schult D, Rasch S, Schmid RM, Lahmer T, Mayr U (2023) EASIX is an accurate and easily available prognostic score in critically ill patients with advanced liver disease. J Clin Med 12(7):2553","journal-title":"J Clin Med"},{"key":"6249_CR80","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, Mcguirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT (2021) Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-Cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22:1403\u20131415","journal-title":"Lancet Oncol"},{"key":"6249_CR81","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","volume":"4","author":"D Sermer","year":"2020","unstructured":"Sermer D, Batlevi C, Lia Palomba M, Shah G, Lin RJ, Perales MA, Scordo M, Dahi P, Pennisi M, Afuye A, Silverberg ML, Ho C, Flynn J, Devlin S, Caron P, Hamilton A, Hamlin P, Horwitz S, Joffe E, Kumar A, Matasar M, Noy A, Owens C, Moskowitz A, Straus D, Von Keudell G, Rodriguez-Rivera I, Falchi L, Zelenetz A, Yahalom J, Younes A, Sauter C (2020) Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv 4:4669\u20134678","journal-title":"Blood Adv"},{"key":"6249_CR82","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ajh.25951","volume":"95","author":"P Sesques","year":"2020","unstructured":"Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhomps A, Karlin L, Brisou G, Vercasson M, Hospital-Gustem C, Schwiertz V, Ranchon F, Rioufol C, Choquet M, Sujobert P, Ghergus D, Bouafia F, Golfier C, Lequeu H, Lazareth A, Novelli S, Devic P, Traverse Glehen A, Viel S, Venet F, Mialou V, Hequet O, Chauchet A, Arkam Y, Nicolas-Virelizier E, Peyrade F, Cavalieri D, Ader F, Ghesqui\u00e8res H, Salles G, Bachy E (2020) Commercial Anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center. Am J Hematol 95:1324\u20131333","journal-title":"Am J Hematol"},{"key":"6249_CR83","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/bjh.18335","volume":"198","author":"L Shargian","year":"2022","unstructured":"Shargian L, Raanani P, Yeshurun M, Gafter-Gvili A, Gurion R (2022) Chimeric antigen receptor T-Cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: a systematic review and meta-analysis. Br J Haematol 198:838\u2013846","journal-title":"Br J Haematol"},{"key":"6249_CR84","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.21.02143","volume":"40","author":"R Shouval","year":"2022","unstructured":"Shouval R, Tomas AA, Fein JA, Flynn JR, Markovits E, Mayer S, Afuye AO, Alperovich A, Anagnostou T, Besser MJ, Batlevi CL, Dahi PB, Devlin SM, Fingrut WB, Giralt SA, Lin RJ, Markel G, Salles G, Sauter CS, Scordo M, Shah GL, Shah N, Scherz-Shouval R, Van Den Brink M, Perales MA, Palomba ML (2022) Impact Of TP53 genomic alterations in large B-Cell lymphoma treated with CD19-chimeric antigen receptor T-Cell therapy. J Clin Oncol 40:369\u2013381","journal-title":"J Clin Oncol"},{"key":"6249_CR85","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/JTO.0b013e318292bdcd","volume":"8","author":"L Simms","year":"2013","unstructured":"Simms L, Barraclough H, Govindan R (2013) Biostatistics primer: what a clinician ought to know-prognostic and predictive factors. J Thorac Oncol 8:808\u2013813","journal-title":"J Thorac Oncol"},{"key":"6249_CR86","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1148\/radiol.2021210760","volume":"302","author":"DA Smith","year":"2022","unstructured":"Smith DA, Kikano E, Tirumani SH, De Lima M, Caimi P, Ramaiya NH (2022) Imaging-based toxicity and response pattern assessment following CAR T-Cell therapy. Radiology 302:438\u2013445","journal-title":"Radiology"},{"key":"6249_CR87","doi-asserted-by":"crossref","unstructured":"Spanjaart AM, Pennings ERA, Mutsaers P, Van Dorp S, Jak M, Van Doesum JA, De Boer JW, Niezink AGH, Kos M, Vermaat JSP, Sijs-Szabo A, Van Der Poel MWM, Nijhof IS, Kuipers MT, Chamuleau MED, Lugtenburg PJ, Doorduijn JK, Serroukh YIM, Minnema MC, Van Meerten T, Kersten MJ (2023) The dutch CAR-T tumorboard experience: population-based real-world data on patients with relapsed or refractory large B-Cell lymphoma referred for CD19-directed CAR T-cell therapy in the Netherlands. Cancers 15(17):4334","DOI":"10.3390\/cancers15174334"},{"key":"6249_CR88","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","volume":"4","author":"P Strati","year":"2020","unstructured":"Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL (2020) Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-Cell lymphoma. Blood Adv 4:3943\u20133951","journal-title":"Blood Adv"},{"key":"6249_CR89","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.2020008865","volume":"137","author":"P Strati","year":"2021","unstructured":"Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS (2021) Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-Cell therapy in large B-Cell lymphoma. Blood 137:3272\u20133276","journal-title":"Blood"},{"issue":"8","key":"6249_CR90","doi-asserted-by":"publisher","first-page":"101158","DOI":"10.1016\/j.xcrm.2023.101158","volume":"4","author":"P Strati","year":"2023","unstructured":"Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS,  Green MR (2023) Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFN \u03b3-expressing CD8 T cells. Cell Rep Med 4(8):101158","journal-title":"Cell Rep Med"},{"key":"6249_CR91","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgu\u00e9s JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G (2022) Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med 386:351\u2013363","journal-title":"N Engl J Med"},{"issue":"18","key":"6249_CR92","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.3390\/cancers15184671","volume":"15","author":"A Trando","year":"2023","unstructured":"Trando A, Ter-Zakarian A, Yeung P, Goodman AM, Hamdan A, Hurley M, Jeong AR, Tzachanis D (2023) Outcomes of chimeric antigen receptor (CAR) T-Cell therapy in patients with large B-Cell lymphoma (LBCL): a single-institution experience. Cancers 15(18):4671","journal-title":"Cancers"},{"issue":"6","key":"6249_CR93","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.3390\/ijms24065688","volume":"24","author":"V Wittibschlager","year":"2023","unstructured":"Wittibschlager V, Bacher U, Seipel K, Porret N, Wiedemann G, Haslebacher C, Hoffmann M, Daskalakis M, Akhoundova D, Pabst T (2023) CAR T-cell persistence correlates with improved outcome in patients with B-Cell lymphoma. Intern J Molecular Sci 24(6):5688","journal-title":"Intern J Molecular Sci"},{"key":"6249_CR94","first-page":"8291","volume":"28","author":"AC Wood","year":"2022","unstructured":"Wood AC, Perez AP, Arciola B, Patel K, Johnson G, Dimaggio E, Bachmeier CA, Reid K, Carallo S, Vargas MH, Faramand R, Chavez JC, Shah B, Gaballa S, Khimani F, Elmariah H, Nishihori T, Lazaryan A, Freeman C, Davila ML, Locke FL, Mhaskar R, Bassil C, Jain MD (2022) Outcomes Of CD19-targeted chimeric antigen receptor T Cell therapy for patients with reduced renal function including dialysis. Trans Cell Therapy 28:8291\u20138298","journal-title":"Trans Cell Therapy"},{"key":"6249_CR95","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","volume":"4","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Pennisi M, Garcia-Recio M, Flynn JR, Afuye A, Silverberg ML, Maloy MA, Devlin SM, Batlevi CL, Shah GL, Scordo M, Palomba ML, Dahi PB, Sauter CS, Santomasso BD, Mead E, Perales MA (2020) DLBCL patients treated with CD19 Car T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv 4:3024\u20133033","journal-title":"Blood Adv"},{"key":"6249_CR96","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5045\/br.2022.2022055","volume":"57","author":"KH Yoo","year":"2022","unstructured":"Yoo KH (2022) Staging and response assessment of lymphoma: a brief review of the lugano classification and the role of FDG-PET\/CT. Blood Res 57:75\u201378","journal-title":"Blood Res"},{"key":"6249_CR97","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/10428194.2021.1986216","volume":"63","author":"H Zhang","year":"2022","unstructured":"Zhang H, Liu M, Li Q, Lyu C, Jiang YY, Meng JX, Li JY, Deng Q (2022) Evaluation of the safety and efficacy of humanized Anti-CD19 chimeric antigen receptor T-Cell therapy in older patients with relapsed\/refractory diffuse large B-Cell lymphoma based on the comprehensive geriatric assessment system. Leukemia Lymphoma 63:353\u2013361","journal-title":"Leukemia Lymphoma"},{"key":"6249_CR98","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/ajh.26718","volume":"97","author":"JC Zurko","year":"2022","unstructured":"Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN (2022) Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-Cells. Am J Hematol 97:1580\u20131588","journal-title":"Am J Hematol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06249-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06249-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06249-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:51:41Z","timestamp":1757209901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06249-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":98,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["6249"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06249-z","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JM, UR and SR were employees of Miltenyi Biomedicine GmbH during the conduct of the study. All authors have no other relevant affiliations or financial involvement with any other organization or entity with a financial interest in the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"203"}}